Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Zoetis Inc. ZTS

Healthcare  —  Drug Manufacturers Specialty & Generic
71.05 0.78 1.11% as of 25 Sep
Market cap
$29.2B
P/E
11.7×
S&P 500 Member Dividend Champion (10y) Revenue Champion (10y) Insider Buys (last 12m)
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Zoetis Inc. (ZTS) Price to free cash flow

As of 25 September 2026, Zoetis Inc. (ZTS) trades at a price to free cash flow of 12.8×. Over the past ten years it has ranged from 12.6× (September 2026) to 69.1× (August 2023); the current reading is higher than 0% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 16.5× and below the Healthcare sector median of 19.5×.

Price to free cash flow, daily

Annual

Period Price to free cash flow Change
FY2025 24.4× (24.11%)
FY2024 32.2× (42.42%)
FY2023 55.9× 7.78%
FY2022 51.9× (22.09%)
FY2021 66.6× 43.37%
FY2020 46.5× (0.45%)
FY2019 46.7× 70.31%
FY2018 27.4× (9.68%)
FY2017 30.3× (32.96%)
FY2016 45.3× (16.47%)

Quarterly

Period Price to free cash flow Change
Jun 2026 12.9× (41.93%)
Mar 2026 22.2× (9.14%)
Dec 2025 24.4× (15.53%)
Sep 2025 28.9× (5.47%)
42 more quarters

Against its own ten years

Low 12.6× High 69.1×
Ten-year median 45.2×
Current reading's percentile 0

Price to free cash flow against peers

Company Price to free cash flow
TAK Takeda Pharmaceutical Co. compare 8.0×
HLN Haleon PLC Sponsored ADR compare 9.4×
VTRS Viatris Inc. compare 11.0×
ZTS Zoetis Inc. 12.8×
NBIX Neurocrine Biosciences, Inc. compare 16.1×
UTHR United Therapeutics Corporation compare 18.6×
ELAN Elanco Animal Health Incorporated compare 31.2×
TEVA Teva Pharmaceutical Industries Ltd. compare 32.6×
RDY Dr. Reddy's Laboratories Ltd compare 69.0×
Drug Manufacturers Specialty & Generic industry median 16.5×
Healthcare sector median 19.5×
Market median 14.0×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

More on ZTS